Evercore ISI analyst Josh Schimmer upgraded Madrigal Pharmaceuticals (MDGL) to Outperform from In Line, stating that he sees recent share price pressure as unjustified and continues to view MGL-3196 as a leading program in the NASH area. He believes the stock's recent weakness is due to confusion on the endpoints presented by the company at the AASLD meeting, a lack of near-term catalysts and the "compelling" results presented by Viking Therapeutics (VKTX) at the liver meeting. While he came away from AASLD with confidence in 3196, he also came away from AASLD realizing there is a tsunami of obesity-related liver complications on the horizon and that "there is absolutely no sign that society is anywhere close to ready to deal with the weight problem," Schimmer tells investors. He raised his price target on Madrigal shares to $250 from $222.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here